

*A<sup>2</sup> accord sub*  
and a pharmaceutically acceptable carrier.

---

*26. sub* 26. (Amended) A method of treating nasal polyps, comprising administering an epidermal growth factor receptor (EGF-R) antagonist that binds an EGF-R to a patient suffering nasal polyps in an amount effective to reduce goblet cell hyperplasia. *From*

---